Iconocast Logo

Welcome To Iconocast

How to add a URL link from your web site to the Iconocast web sites

Virtual tour of Southern California

 

Recent News and Articles on the Keywords: lupus treatment + lupus + treatment  Related to the article below (Last Update: 8/5/2008)

Learning to live with lupus
CNN -
When Harned's lupus was first diagnosed, she said she "was really terrified, but gradually I got more information." She realized with proper treatment she ...
Earnings roundup: Cooper Tire & Rubber, Nicor
Forbes, NY -
SAN DIEGO (AP) - La Jolla Pharmaceutical Co. said Monday its second-quarter loss grew as the cost of testing its lupus treatment candidate Riquent ...CTB - GAS
Single-Pill Combinations Diovan HCT and Exforge Approved in US as ...
MarketWatch - Aug 3, 2008
Tell your doctor about all your medical conditions and medicines you take, including liver or kidney problems, lupus or if you take lithium. ...
La Jolla Pharmaceutical Company Reports Second Quarter and Year-to ...
Business Wire (press release), CA - Aug 4, 2008
The analyses of clinical results of Riquent ? (abetimus sodium), previously known as LJP 394, our drug candidate for the treatment of systemic lupus ...LJPC
La Jolla Pharma 2Q loss rises on research costs
CNNMoney.com -
NEW YORK (Associated Press) - La Jolla Pharmaceutical Co. said Monday its second-quarter loss grew as the cost of testing its lupus treatment candidate ...LJPC
Hadasit Bio firm Verto completes Lupus treatment trial
Globes, Israel - Jul 21, 2008
The company is developing the Lupusorb for the treatment of systemic lupus erythematosus. The device is a filter column that can be incorporated into the ...TLV:HDST
Zim commended for spirited fight against HIV/Aids
The Herald, Zimbabwe - Aug 4, 2008
It is naturally produced by people, like lupus patients. When they applied that abzyme to the HIV virus, it permanently disarmed it. ...
Lupus Treatment
NewsChannel 9 WSYR, NY - Jul 21, 2008
The disease is Lupus and researchers may be closing in on the first new treatment in nearly half a century. That's tonight in the "Family Healthcast. ...
Top-Line Results of Boceprevir Phase II Study Showed High Rate of ...
CNNMoney.com (press release) -
In a 48-week treatment regimen, the SVR rate at 12 weeks after the end of treatment (SVR 12) was 74 percent (ITT) in patients who received 4 weeks of ...SGP
Dr. Jeff Hersh: The skin is a complex system
Norwich Bulletin, CT -
The goal of treatment of BP is to minimize blister formation, promote healing of the blisters that do form and to prevent complications. ...
Source: Google News

Treatment of murine lupus with CTLA4Ig -
BK Finck, PS Linsley, D Wofsy - Science, 1994 - sciencemag.org
... articles. Treatment of murine lupus with CTLA4Ig. ... 74: 8349-8357 | Abstract ? | Full
Text ? Treatment of murine lupus with cDNA encoding IFN-{gamma}R/Fc. ...

… renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide … -
AD Steinberg, SC Steinberg - Arthritis Rheum, 1991 - ncbi.nlm.nih.gov
... 1992 May;35(5):605-7. Long-term preservation of renal function in patients with
lupus nephritis receiving treatment that includes cyclophosphamide versus those ...

B cell depletion as a novel treatment for systemic lupus erythematosus -
RJ Looney, JH Anolik, D Campbell, RE Felgar, F … - Arthritis Rheum, 2004 - doi.wiley.com
... treatment. Rituximab treatment did not have an adverse Figure 3. Resolution
of proliferative lupus nephritis after rituximab treatment. A ...

In vivo treatment of (NZB X NZW) F1 lupus-like nephritis with monoclonal antibody to gamma … -
CO Jacob - Journal of Experimental Medicine, 1987 - Rockefeller Univ Press
... Hadaya, S. Ezine, E. Schneider, O. Babin, and JF Bach Granulocyte-Colony Stimulating
Factor Treatment of Lupus Autoimmune Disease in MRL-lpr/lpr Mice J. Immunol ...

Amelioration of lupus-like autoimmune disease in NZB/WF1 mice after treatment with a blocking … -
Y Wang, Q Hu, JA Madri, SA Rollins, A Chodera, LA … - Proceedings of the National Academy of Sciences of the …, 1996 - pubmedcentral.nih.gov
... Immunol Res. 1993;12(3):244?257. [PubMed]; Finck BK, Linsley PS, Wofsy D. Treatment
of murine lupus with CTLA4Ig. Science. 1994 Aug 26;265(5176):1225?1227. ...

… of Fc RIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus … -
JH Anolik, D Campbell, RE Felgar, F Young, I Sanz, … - Arthritis Rheum, 2003 - doi.wiley.com
... Treatment of Systemic Lupus Erythematosus Jennifer H. Anolik, 1 Debbie Campbell,
1 Raymond E. Felgar, 1 Faith Young, 1 Inaki Sanz, 1 ...

Treatment of lupus nephritis: a meta-analysis of clinical trials. -
VK Bansal, JA Beto - Am J Kidney Dis, 1997 - ncbi.nlm.nih.gov
Am J Kidney Dis. 1997 Feb;29(2):193-9. Treatment of lupus nephritis: a
meta-analysis of clinical trials. Bansal VK, Beto JA. Division ...

Experimental therapy of systemic lupus erythematosus: the treatment of NZB/W mice with mouse soluble … -
L Ozmen, D Roman, M Fountoulakis, G Schmid, B … - Eur J Immunol, 1995 - ncbi.nlm.nih.gov
Experimental therapy of systemic lupus erythematosus: the treatment of NZB/W mice
with mouse soluble interferon-gamma receptor inhibits the onset of ...

Treatment of severe systemic lupus erythematosus with high-dose chemotherapy and haemopoietic stem- … -
AE Traynor, J Schroeder, RM Rosa, D Cheng, J … - The Lancet, 2000 - Elsevier
... T-cell responsiveness to in-vitro stimulation and a T-helper-2 skewing has previously
been shown to characterise active lupus irrespective of treatment state. ...

Possible induction of systemic lupus erythematosus by interferon-alpha treatment in a patient with a … -
LE Ronnblom, GV Alm, KE Oberg - J Intern Med, 1990 - ncbi.nlm.nih.gov
Possible induction of systemic lupus erythematosus by interferon-alpha treatment
in a patient with a malignant carcinoid tumour. Ronnblom LE, Alm GV, Oberg KE. ...

Source: Google Scholar

MedImmune Advances Potential Treatment For Patients With Lupus
MedImmune, Inc. today announced that it has begun dosing patients in a multi-dose, Phase 1b clinical trial with its monoclonal antibody (MAb) targeting interferon-alpha, known as MEDI-545. The study is designed to evaluate the safety and tolerability of multiple doses of the MAb in patients with systemic lupus erythematosus (SLE or lupus). The trial is the third clinical study underway with the antibody, which is also being evaluated in a single-dose Phase 1 trial in lupus patients and a Phase 1 study in patients with psoriasis.

"This multi-dose study marks an important milestone in MedImmune's efforts to develop innovative treatments for inflammatory diseases such as lupus," said Barbara White, vice president, clinical development, inflammatory disease. "Our therapeutic approach to addressing this area of high unmet medical need is supported by increasing evidence of type-1 interferon involvement in the pathology of immune system disorders, and we are pleased to extend clinical evaluation of our anti-interferon-alpha MAb to a second Phase 1 study in this patient population."
The Phase 1b trial will build on preliminary data from the ongoing Phase 1 study in lupus patients, as described in a presentation at the 8th International Lupus Consortium held May 24-26, 2007 in Shanghai. Early results from the single-dose trial show an acceptable safety profile and tolerability of MEDI-545.

In addition to advancing MEDI-545 as a potential treatment for lupus, with two Phase 1 trials underway, MedImmune has recently expanded the anti-interferon-alpha program to include other potential disease areas. The company initiated a Phase 1 trial in patients with psoriasis earlier in 2007 and plans to begin a trial in idiopathic inflammatory myopathies later this year.

About Anti-Interferon-Alpha MAb

MEDI-545 is a fully human MAb targeting interferon-alpha. Published data indicate that levels of interferon-alpha are elevated in many patients with active SLE and other autoimmune disorders, and may be associated with disease activity. Preclinical data from animal models suggest that MEDI-545 may suppress the abnormal immune activity associated with lupus by binding to the pattern of multiple interferon-alpha subtypes seen in the serum of lupus patients.

About Lupus

Approximately 350,000 individuals in the United States are affected with lupus, a chronic inflammatory disease that causes the body to attack its own tissues and organs, including the skin, joints, blood and kidneys. Treatments for lupus include anti-inflammatory drugs, antimalarials, corticosteroids and drugs approved for other purposes, such as immunosuppressive agents given to cancer patients undergoing chemotherapy or medicines developed to treat arthritis patients. Lupus occurs about 10 times more frequently in adult females than adult males, and is two to three times more common among African Americans, Hispanics, Asians and Native Americans.

About MedImmune, Inc.

MedImmune strives to provide better medicines to patients, new medical options for physicians and rewarding careers to employees. Dedicated to advancing science and medicine to help people live better lives, the company is focused on the areas of infectious diseases, cancer and inflammatory diseases. With approximately 3,000 employees worldwide, MedImmune is headquartered in Maryland. For more information, visit the company's website at http://www.medimmune.com.

MedImmune, Inc.
http://www.medimmune.com
 
 
 
Google
Web www.iconocast.com

Search inside Iconocast for the keyword you have in mind.

Iconocast has collected more than 50,000 articles and press releases on health and science.

These are current and most up to date press releases on the subject you are searching.

We collect current health and science press releases daily from more than 5000 research and health institutes. Here is an example : The elderberry way to perfect skin

We believe if you do search inside Iconocast, you will get better results than searching the web alone.

 
 
Continue News With: News9 ; News9A


ADVERTISEMENT

Iconocast is about learning and teaching without borders; we offer eMarketing, Internet Advertising, Internet Marketing, Search Engine Optimization, Search Engine Marketing, Online Branding, and eMarketing News Services.

 

Iconocast Home Page

Contact Iconocast

© 2003-07. ICONOCAST is a trademark of iconocast.com.